June 2020


The celebratory success of our Single Day Events so far speaks for itself. Spring House, Pune, Frenchtown and Bengaluru have all hosted more than quadruple their physical capacity. The virtualisation welcomed an amazing 1,700+ attendees, in comparison to the 400-person capped physical capacity.

Impact of the COVID-19 Pandemic and Collection/Analysis of Laboratory Data in Ongoing Clinical Trials

Since late 2019/early 2020, the global COVID-19 pandemic has impacted all aspects of daily life. Ongoing clinical trials have been impacted in multiple ways, including but not limited to delays in screening and enrolment of subjects into trials, challenges with maintaining the trial schedule for ongoing subjects due to temporary site closures, lack of continuous drug supply, and subjects experiencing new and unexpected adverse events. The safety of clinical trial participants must be ensured despite these challenges.

Your Guide to ON24

The virtual-event world is the new normality for 2020; with in-person events postponed or cancelled, we have all had to adjust to a virtual environment. During this time, when being able to connect face-to-face is impossible, PHUSE is doing all it can to continue to provide the highest standards of event experience to our attendees. We have sourced the industry-leading platform ‘ON24’ to ensure the PHUSE Community remains connected across the world in an interactive, digital environment, with the familiar feel of a PHUSE event to your device.

Impact of the COVID-19 Pandemic and Collection/Analysis of Adverse Events Data in Ongoing Trials

This blog considers the impacts of COVID-19 on the collection and analysis of adverse events, offering guidance from industry experts on what clinical data scientists [1] (i.e. those who analyse data collected in clinical trials) can expect in the short term relating to the studies impacted by the COVID-19 pandemic, as well as consideration of future implications.

Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19

With the COVID-19 pandemic thoughts have turned to how to address the impact of the virus and measures taken to suppress it have had on clinical studies. In the last few weeks two papers providing analysis recommendations from clinical trials impacted by COVID-19 have been prepared by a cross-industry group and submitted to Statistics in Biopharmaceutical Research.


Thinking of joining PHUSE?

Already a member but not sure how you can benefit?

PHUSE is an expanding, global society with a global membership of clinical data scientists. It requires a large pool of resources to help with its running, and so there are many opportunities for members to become involved. Whether it's chairing a conference, presenting at an event, leading a working group or contributing to the quarterly online newsletter, we are always keen to hear from volunteers.

Find Out More